- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
Expert Details the Top 3 CV Complications Seen in Patients with Obesity
"What are the most common cardiovascular complications you see in patients with obesity?"
That is the question Patient Care Online recently asked Alina Elperin, MD, in an interview. Dr Elperin is an internest and obesity medicine specialist in Evanston, Illinois, as well as a Clinical Assistant Professor at the University of Chicago Pritzker School of Medicine.
In the video below, Dr Elperin details the top 3 cardiovascular complications that she has observed in patients with obesity for clinicians to keep in mind.
FDA Approves First Oral GLP-1 Receptor Agonist for Chronic Weight Management
December 23rd 2025The FDA approved once-daily oral semaglutide 25 mg for chronic weight management and long-term weight maintenance in adults with obesity or overweight, based on data from the OASIS clinical trial program.
Phase 3 Data Support Oral Orforglipron for Weight Maintenance After GLP-1–Based Weight Loss
December 19th 2025Topline Phase 3 ATTAIN-MAINTAIN data show oral orforglipron met primary and key secondary endpoints for weight maintenance after prior GLP-1–based injectable therapy in adults with obesity.
